Explore our
BioLizard Appoints Matthew Hall as Director of Business Development
BioLizard welcomes Dr. Matthew Hall as Director of Business Development. With deep experience in Swiss biotech, AI, and strategic partnerships, Matthew will drive BioLizard’s growth across key markets and strengthen our presence at Biopôle and beyond. Meet him at Swiss Biotech Day!
Single-cell vs. bulk sequencing: which one to use when?
In 2013, Nature Methods Method of the Year crowned single-cell sequencing as its Method of the Year and the field hasn’t looked back since. What was once impossible is now routine: profiling thousands of individual cells to uncover heterogeneity that bulk approaches simply average out.
Yet progress doesn’t mean replacement. Bulk sequencing still delivers robust, cost-effective insights at scale, while single-cell methods reveal the cellular players driving disease. The real power lies not in choosing one over the other, but in understanding when, and how, to use both.
BioLizard and AbnomX announce partnership
BioLizard and AbnomX announce a strategic partnership to accelerate antibody discovery. Combining BioLizard’s advanced analytics with AbnomX’s Antibody-Extractor platform, the collaboration empowers scientists to transform immune repertoire data into actionable insights.
From enigma to insight: How explainable AI can help us unravel biological complexity
Discover how explainable AI helps scientists move beyond black-box predictions to uncover the why behind biological insights. Learn how BioLizard’s Bio|Mx platform combines transparency, AI, and human expertise to drive smarter, data-informed R&D decisions.
Strategic AI for single cell sequencing & multi-omics advances
Discover how AI is revolutionizing single cell sequencing and multi-omics research. Learn how BioLizard’s Bio|Mx platform blends AI innovation with human expertise to unlock deeper biological insights, accelerate drug discovery, and advance precision medicine.
BioLizard joins BioWin
BioLizard has joined BioWin, Wallonia’s leading health cluster, to collaborate with innovators in biotech, medtech, and research. This partnership strengthens our mission to leverage data for better health outcomes and accelerate life sciences innovation in the region.
AI in the life sciences: (Un)limited potential?
Explore the potential and challenges of AI in drug discovery. BioLizard highlights the importance of high-quality data, human-AI collaboration, and tailored strategies to transform complex biomedical data into actionable insights for more efficient and effective R&D.
BioLizard announces the appointment of André van de Sande as Chairman of the Board
BioLizard appoints André van de Sande as Chairman of the Board. With 30 years of global life sciences experience and a proven track record in pharma, biotech, and consulting, André will guide BioLizard’s international expansion and support its mission in bioinformatics and data-driven life sciences.
BioLizard announces Swiss subsidiary and service offering for AI-powered digital transformation of life sciences at Biopôle in Lausanne
BioLizard launches Swiss subsidiary BioLizard SA at Biopôle in Lausanne, expanding its international presence. The new office offers AI-powered digital transformation services, bioinformatics, and multi-omics solutions to support Swiss biotech clients in drug discovery, diagnostics, and research.
Trends in single cell sequencing: Spatial transcriptomics
Spatial transcriptomics is emerging as a key trend in single cell sequencing, offering powerful insights into tissue biology and tumor microenvironments. Despite challenges in cost, complexity, and analytics, growing standardization will drive adoption. BioLizard already leads in expert analysis.